Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Combining Multiple Laboratory Techniques Provides Deeper Insights into Deadly Brain Tumors

By LabMedica International staff writers
Posted on 15 May 2025

Glioblastoma (GBM) is a highly aggressive primary brain cancer that currently has limited effective treatments. More...

Stereotactic needle biopsies are commonly employed for diagnosis; however, their use is restricted as physicians typically limit the collection of small tumor samples due to the invasive nature of the procedure, which requires sedation with anesthesia. Tumor samples are usually obtained at the start of treatment and, occasionally, at the end. In a groundbreaking study, a team of researchers has shown that doctors can gather extensive information about a patient’s cancer by applying various laboratory techniques to analyze tumor tissue obtained from needle biopsies of glioblastoma. This work, published in Nature Communications, could also have significant implications for diagnosing and studying other types of cancer.

In the study, clinicians from Johns Hopkins Kimmel Cancer Center (Baltimore, MD, USA) and four other institutions injected a virus designed to target and kill glioblastoma cells directly into the tumor. During the same procedure, surgeons collected tumor tissue samples, which were then analyzed using multiple advanced laboratory techniques, including single-cell RNA sequencing, transcriptomics, metabolomics, proteomics, and immune profiling. These techniques allowed the researchers to demonstrate that even small samples of tumor tissue could provide valuable insights into the tumor's biological characteristics, immune interactions, and molecular pathways. Additionally, the study found that the tissue could be grafted onto a mouse model for further examination and analysis.

“This is a concept that expands beyond just brain cancers,” said study co-author Chetan Bettegowda, M.D., Ph.D. “Whenever people do needle biopsies, it has been just sufficient to study if the tissue is cancerous, what type and maybe some very simple molecular characterization. This brings tissue analysis to the modern age. ... Historically [oncologists] haven’t done repeat biopsies because we felt, ‘Oh, what are we going to get that we don’t already know from the original diagnosis?’ It turns out there’s quite a bit to be learned.”

Related Links:
Johns Hopkins Kimmel Cancer Center


Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Laboratory Software
ArtelWare
Rapid Molecular Testing Device
FlashDetect Flash10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.